doxorubicin + vorinostat

Doxorubicin + vorinostat is a combination therapy that pairs doxorubicin, an anthracycline chemotherapeutic agent that inhibits topoisomerase II, with vorinostat, a histone deacetylase (HDAC) inhibitor. The therapeutic rationale involves vorinostat-induced histone acetylation and chromatin modulation, which facilitates DNA access and target recruitment for topoisomerase II inhibitors like doxorubicin. This sequence-specific combination has been studied in clinical trials for various solid tumors including breast cancer, melanoma, and prostate cancer, as well as multiple myeloma when combined with additional agents.